Sarah Jones, Head of Education and Academic Liaison at ABPI, said: ‘It is vital that research-led science based companies are able to recruit the specialists that they need for the business to thrive. Intra-company transfers play a key role in this while also helping to bring in new skills which subsequently help to upskill other employees.
21 Jan 2016 Posted in News Release By Press Office
"At ABPI we believe that any new restriction on movement for key roles would certainly have a major adverse effect on the economic health of companies based in UK. Therefore we would strongly oppose efforts to enforce this."
The report, which cites the recent ABPI report – Bridging the skills gap in the biopharmaceutical industry – which found that pharmaceutical companies are struggling to recruit for high skilled roles in the UK due to low numbers of good quality candidates.
Sarah Jones added: "Securing the appropriate skills and roles across manufacturing, clinical and research and development within life sciences has been a significantly growing concern for our sector in the UK. Working to secure a skilled UK workforce for the future of biosciences is challenging and having the ability to utilise skills from outside of the EU is vital."
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.